Endocyte, Inc. (ECYT) Expected to Announce Earnings of -$0.16 Per Share
Equities analysts forecast that Endocyte, Inc. (NASDAQ:ECYT) will report earnings per share of ($0.16) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Endocyte’s earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.16). Endocyte reported earnings per share of ($0.26) during the same quarter last year, which would suggest a positive year over year growth rate of 38.5%. The company is expected to issue its next quarterly earnings report on Friday, March 9th.
According to Zacks, analysts expect that Endocyte will report full year earnings of ($1.24) per share for the current fiscal year, with EPS estimates ranging from ($1.25) to ($1.23). For the next year, analysts expect that the firm will report earnings of ($0.91) per share, with EPS estimates ranging from ($1.02) to ($0.79). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Endocyte.
Endocyte (NASDAQ:ECYT) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.20). Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. The business had revenue of $0.03 million during the quarter. During the same period in the previous year, the business posted ($0.21) EPS. The business’s quarterly revenue was up .0% compared to the same quarter last year.
A number of analysts have recently weighed in on ECYT shares. Cowen restated a “hold” rating on shares of Endocyte in a research note on Monday, October 2nd. Zacks Investment Research upgraded Endocyte from a “sell” rating to a “hold” rating in a research report on Thursday, November 9th. Wedbush upgraded Endocyte from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $2.00 to $7.00 in a research report on Tuesday, October 3rd. Finally, ValuEngine upgraded Endocyte from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd.
Shares of Endocyte (NASDAQ ECYT) traded down $0.11 during trading hours on Friday, hitting $4.09. The stock had a trading volume of 704,426 shares, compared to its average volume of 460,083. Endocyte has a 52 week low of $1.17 and a 52 week high of $6.55. The firm has a market capitalization of $178.82, a price-to-earnings ratio of -3.03 and a beta of 2.20.
In related news, VP Christopher P. Leamon sold 23,231 shares of Endocyte stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $5.04, for a total value of $117,084.24. Following the completion of the sale, the vice president now directly owns 150,579 shares in the company, valued at $758,918.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Philip S. Low acquired 5,600 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average price of $4.84 per share, with a total value of $27,104.00. Following the completion of the transaction, the insider now owns 283,005 shares of the company’s stock, valued at $1,369,744.20. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 124,253 shares of company stock valued at $562,591. Corporate insiders own 14.86% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its position in Endocyte by 34.1% in the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 25,003 shares during the period. FMR LLC increased its position in Endocyte by 0.9% in the second quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock worth $5,310,000 after purchasing an additional 31,168 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Endocyte by 1,064.3% in the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock worth $646,000 after purchasing an additional 393,975 shares during the period. Hedge funds and other institutional investors own 17.58% of the company’s stock.
Endocyte Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.